Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of dAd5GNE Anti-cocaine Vaccine
NCT02455479Phase 1Recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Sep 2016
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dAd5GNE in cocaine dependence (3 cohorts), sponsored by Weill Cornell Medicine. Primary endpoint: Safety of dAd5GNE vaccine at 32 weeks. Started Sep 2016; status: recruiting.
02
Drugs
dAd5GNE
03
Conditions
cocaine dependence
Beyond the preview
Go deeper on NCT02455479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02455479.